Retrospective Observational Study Of Subjects With Cytokine-Refractory Metastatic Renal Cancer Treated With Axitinib (AG-013736) To Estimate 5-Yr Survival
Subjects participating in this observational study originally participated in study A4061012
[NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
Subjects participating in this observational study originally participated in study A4061012
[NCT00076011], and may have also have participated in study A4061008 [NCT00828919].
5-year survival information to be updated.
Observational
Time Perspective: Retrospective
Overall Survival (OS)
Overall survival is the duration from first dose of study medication to death. For participants who are alive, overall survival is censored at the last contact.
Baseline until death or up to Year 5
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A4061065
NCT01056263
April 2010
December 2010
Name | Location |
---|---|
Pfizer Investigational Site | Blendora, California 91740 |
Pfizer Investigational Site | Cincinnait, Ohio 45236 |
Pfizer Investigational Site | Bronx, New York 10461 |
Pfizer Investigational Site | North Adams, Massachusetts 01247 |
Pfizer Investigational Site | Milwaukee, Wisconsin 53215 |